Raltegravir: The evidence of its therapeutic value in HIV-1 infection

References

• UNAIDS. Report on the global HIV/AIDS epidemic 2008: executive summary. 2008. Accessed February 2008. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp.
   Google Scholar
• Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358: 2095–2106.
   PubMed Web of Science ®Google Scholar
• Emmelkamp JM, Rockstroh JK. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin Drug Safety. 2008;7: 559–569.
   PubMed Web of Science ®Google Scholar
• Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis. 2008;47:969–978.
   PubMed Web of Science ®Google Scholar
• Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2008;6:427–433.
   PubMed Web of Science ®Google Scholar
• Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS. 2008;22:459–471.
   PubMed Web of Science ®Google Scholar
• Montessori V, Press N, Harris M, Akagi LMontaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170: 229–238.
   PubMed Web of Science ®Google Scholar
• Young B. Review: mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS. 2005;19:286–297.
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–2062.
   Web of Science ®Google Scholar
• Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–231.
   PubMed Web of Science ®Google Scholar
• Gross R, Yip B, Lo Re V 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–1114.
   PubMed Web of Science ®Google Scholar
• Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract]. Toronto, Canada: XVI International AIDS Conference; 2006. THAA0302.
   Google Scholar
• Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51:5843–5855.
   PubMed Web of Science ®Google Scholar
• Cabrera C. Raltegravir, an HIV-1 integrase inhibitor for HIV infection. Curr Opin Investig Drugs. 2008;9:885–898.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008e;83:293–299.
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657–1663.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509–515.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–133.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data [abstract]. Mexico City, Mexico: XVII International AIDS Conference; 2008. TUAB0102.
   Google Scholar
• Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-Infected Patients [abstract]. Washington, DC: 48th Annual ICAAC/IDSA 46th Annual Meeting; 2008. H-896a.
   Google Scholar
• Lennox J, Dejesus E, Lazzarin A, et al. Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenzbased Combination Therapy in Treatment-naïve HIV-infected Patients [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunisitic Infections; 2009. 573.
   Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–1269.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Steigbigel R, Cooper D, Eron J, et al. 96-week results from BENCHMRK 1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV [abstract]. 16th Conference on Retroviruses and Opportunistic Infections; 2009. 571B.
   Google Scholar
• Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315–2321.
   PubMed Web of Science ®Google Scholar
• Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A. 2008;105:4832–4837.
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008b;22:1224–1226.
   PubMed Web of Science ®Google Scholar
• De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in highly treatement experienced HIV-1-infected patients: a randomized open-label non-inferiority trial, EASIER – ANRS 138 [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunistic Infections; 2009. 572.
   Google Scholar
• Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir-based to raltegravir-based combination art resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada. 2009. Abstract 70aLB.
   Google Scholar
• Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914–920.
   PubMed Web of Science ®Google Scholar
• Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS. 2008;22:1091–1092.
   PubMed Web of Science ®Google Scholar
• Goodman DD, Hluhanich R, Waters J, et al. Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance XVII International HIV Drug Resistance Workshop; Sitges, Spain. Antiviral Ther. 2008;13:A15.
   Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351–1358.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528–532.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12:563–570.
   PubMed Web of Science ®Google Scholar
• Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol. 2008;82:9228–9235.
   PubMed Web of Science ®Google Scholar
• Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Cladespecific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS. 2008;22: 1877–1880.
   PubMed Web of Science ®Google Scholar
• Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008;47:9345–9354.
   PubMed Web of Science ®Google Scholar
• Zahm JA, Bera S, Pandey KK, et al. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother. 2008;52:3358–3368.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008c;47:137–140.
   PubMed Web of Science ®Google Scholar
• Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52:3253–3258.
   PubMed Web of Science ®Google Scholar
• Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir [abstract]. Mexico City, Mexico: XVII International AIDS Conference; 2008. TUPE0087.
   Google Scholar
• Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008a;48:209–214.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Iwamoto M, Wenning L. Emerging pharmacology: Inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol. 2008;49:377–394.
   Web of Science ®Google Scholar
• Anderson MS, Wenning LA, Moreau A, et al. Effect of raltegravir (RAL) on the pharmacokinetics (PK) of oral contraceptives [abstract]. Chicago, IL: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007. 4731.
   Google Scholar
• Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009b;48:489–492.
   PubMed Web of Science ®Google Scholar
• Teppler H, Azrolan N, Chen J, Nguyen NY. Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients [abstract]. San Francisco, CA: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. H-256a.
   Google Scholar
• Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22: 1382–1384.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008b;48:726–733.
   PubMed Web of Science ®Google Scholar
• Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008;28:90–101.
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008a;22: 1890–1892.
   PubMed Web of Science ®Google Scholar
• Cooper D, Steigbigel R, Lennnox J, et al. Review of cancer incidence in raltegravir clinical trials [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunistic Infections; 2009. 859.
   Google Scholar
• Common Drug Review. Raltegravir (IsentressTM – Merck Frosst Canada Ltd.), Indication – HIV infection: Overview of CDR and Pharmacoeconomic reports [July 2008]. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2008.
   Google Scholar
• Elbasha E, Szucs T, Chaudhary M, et al. Cost-effectiveness analysis of Raltegravir in treatment – experienced HIV-1 infected patients in Switzerland [abstract]. Mexico City, Mexico: Poster Discussion: AIDS 2008 – XVII International AIDS Conference;2008. TUPDD203.
   Google Scholar
• Martin SC. Cost-minimization analysis of etravirine and raltegravir, two new HIV treatments for treatment-experienced patients. Value in Health. 2008;11:A438–A438.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: CDC, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008a. NGC:006760.
   Google Scholar
• Centers for Disease Control and Prevention. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda, MD: CDC, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008b. NGC:006652.
   Google Scholar
• New York State Department of Health. Drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs. New York, NY: New York State Department of Health. 2008. NGC:006471.
   Google Scholar
• Anon. Raltegravir Prescribing Information. 2009. Accessed Feb 2009. Available from: http://www.merck.com/.
   Google Scholar
• Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009a;53:1747–1752.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008d;52:4338–4343.
   PubMed Web of Science ®Google Scholar
• Rhame F, Long M, Acosta E. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults [abstract]. New Orleans, LA: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008. O19.
   Google Scholar
• Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir (tpv + Rtv) on pharmacokinetics of MK-0518 [abstract]. San Francisco, CA: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. A374.
   Google Scholar
• Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52:4228–4232.
   PubMed Web of Science ®Google Scholar